Porfimer Sodium

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 100750

CAS#: 87806-31-3 (sodium)

Description: Porfimer sodium is t he sodium salt of a mixture of oligomers formed by ether and ester linkages of up to eight porphyrin units with photodynamic activity. Absorbed selectively by tumor cells, porfimer produces oxygen radicals after activation by 630 nm wavelength laser light, resulting in tumor cell cytotoxicity. In addition, tumor cell death may occur due to ischemic necrosis secondary to vascular occlusion that appears to be partly mediated by the release of thromboxane A2.

Chemical Structure

Porfimer Sodium
CAS# 87806-31-3 (sodium)

Theoretical Analysis

MedKoo Cat#: 100750
Name: Porfimer Sodium
CAS#: 87806-31-3 (sodium)
Chemical Formula:
Exact Mass:
Molecular Weight:
Elemental Analysis:

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 97067-70-4 (acid)   87806-31-3 (sodium)  

Synonym: CL184116; CL-184116; CL 184116; DHE; dihematoporphyrin ether; Porfimer. Brand name: Photofrin; Photofrin II.

IUPAC/Chemical Name: 3,3'-(12-(1-(1-(2,18-bis(2-carboxyethyl)-12-(1-hydroxyethyl)-3,8,13,17-tetramethylporphyrin-7-yl)ethoxy)ethyl)-7-(1-hydroxyethyl)-3,8,13,17-tetramethylporphyrin-2,18-diyl)dipropionic acid


InChi Code: InChI=1S/C68H74N8O11/c1-29-41(13-17-61(79)80)53-28-56-44(16-20-64(85)86)32(4)48(72-56)24-59-68(36(8)52(76-59)25-58-65(37(9)77)33(5)49(73-58)21-45(29)69-53)40(12)87-39(11)67-35(7)50-22-46-30(2)42(14-18-62(81)82)54(70-46)27-55-43(15-19-63(83)84)31(3)47(71-55)23-57-66(38(10)78)34(6)51(74-57)26-60(67)75-50/h21-28,37-40,71-73,75,77-78H,13-20H2,1-12H3,(H,79,80)(H,81,82)(H,83,84)(H,85,86)/b45-21-,46-22-,47-23-,48-24-,49-21-,50-22-,51-26-,52-25-,53-28-,54-27-,55-27-,56-28-,57-23-,58-25-,59-24-,60-26-

SMILES Code: O=C(O)CCC1=C2/C=C3C(CCC(O)=O)=C(C)C(/C=C(N/4)/C(C)=C(C(O)C)C4=C\C5=N/C(C(C(OC(C6=C7/C=C8C(C)=C(C(O)C)C(/C=C(N/9)/C(C)=C(CCC(O)=O)C9=C\C%10=N/C(C(C)=C%10CCC(O)=O)=C\C(N7)=C6C)=N/8)C)C)=C5C)=C\C(N2)=C1C)=N/3

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Ito A, Kimura T, Miyoshi S, Ogawa S, Arai T. Photosensitization reaction-induced acute electrophysiological cell response of rat myocardial cells in short loading periods of talaporfin sodium or porfimer sodium. Photochem Photobiol. 2011 Jan-Feb;87(1):199-207. doi: 10.1111/j.1751-1097.2010.00846.x. Epub 2010 Nov 29. PubMed PMID: 21114668.

2: Pereira SP, Ayaru L, Ackroyd R, Mitton D, Fullarton G, Zammit M, Grzebieniak Z, Messmann H, Ortner MA, Gao L, Trinh MM, Spénard J. The pharmacokinetics and safety of porfimer after repeated administration 30-45 days apart to patients undergoing photodynamic therapy. Aliment Pharmacol Ther. 2010 Sep;32(6):821-7. doi: 10.1111/j.1365-2036.2010.04400.x. PubMed PMID: 20629974; PubMed Central PMCID: PMC2978022.

3: Yumita N, Han QS, Umemura S. Sonodynamically induced apoptosis with porfimer sodium in HL-60 cells. Anticancer Drugs. 2007 Nov;18(10):1149-56. PubMed PMID: 17893515.

4: Mino-Kenudson M, Ban S, Ohana M, Puricelli W, Deshpande V, Shimizu M, Nishioka NS, Lauwers GY. Buried dysplasia and early adenocarcinoma arising in barrett esophagus after porfimer-photodynamic therapy. Am J Surg Pathol. 2007 Mar;31(3):403-9. PubMed PMID: 17325482.

5: Stoev G, Stoyanov A, Shopova M, Dachev K. Identification of porphyrin modified photosensitizer porfimer sodium and its precursors by high performance liquid chromatography and mass spectrometry. J Chromatogr A. 2007 Mar 23;1145(1-2):141-8. Epub 2007 Jan 26. PubMed PMID: 17303147.

6: Ohmori S, Arai T. In vitro behavior of Porfimer sodium and Talaporfin sodium with high intensity pulsed irradiation. Lasers Med Sci. 2006 Dec;21(4):213-23. Epub 2006 Sep 22. PubMed PMID: 17024319.

7: Shah AK, Wolfsen HC, Hemminger LL, Shah AA, DeVault KR. Changes in esophageal motility after porfimer sodium photodynamic therapy for Barrett's dysplasia and mucosal carcinoma. Dis Esophagus. 2006;19(5):335-9. PubMed PMID: 16984528.

8: Houle JM, Clervoix N, Bain S, Spénard J. Lack of effect of sex and disease state on the pharmacokinetics of porfimer sodium. Clin Pharmacokinet. 2006;45(9):923-30. PubMed PMID: 16928153.

9: Oseroff AR, Blumenson LR, Wilson BD, Mang TS, Bellnier DA, Parsons JC, Frawley N, Cooper M, Zeitouni N, Dougherty TJ. A dose ranging study of photodynamic therapy with porfimer sodium (Photofrin) for treatment of basal cell carcinoma. Lasers Surg Med. 2006 Jun;38(5):417-26. PubMed PMID: 16788928.

10: Panjehpour M, Overholt BF. Porfimer sodium photodynamic therapy for management of Barrett's esophagus with high-grade dysplasia. Lasers Surg Med. 2006 Jun;38(5):390-5. PubMed PMID: 16788927.

Additional Information

The purified component of HEMATOPORPHYRIN DERIVATIVE, it consists of a mixture of oligomeric porphyrins. It is used in photodynamic therapy (HEMATOPORPHYRIN PHOTORADIATION); to treat malignant lesions with visible light and experimentally as an antiviral agent. It is the first drug to be approved in the use of PHOTODYNAMIC THERAPY in the United States.